

Ashish Sharma

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6487346/publications.pdf>

Version: 2024-02-01

57
papers

685
citations

706676

14
h-index

759306

22
g-index

58
all docs

58
docs citations

58
times ranked

542
citing authors

#	ARTICLE	IF	CITATIONS
1	Biosimilar anti-VEGFâ€”Yardsticks to ensure biosimilarity. <i>Eye</i> , 2023, 37, 4-5.	1.1	1
2	Understanding Retinal Vasculitis Associated with Brolicizumab: Complex Pathophysiology or Occamâ€™s Razor?. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1508-1510.	1.0	16
3	Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). <i>Eye</i> , 2022, 36, 1106-1107.	1.1	11
4	Faricimab: Two in the Bush Is Proving Better than One in the Hand?. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1961-1963.	1.0	4
5	FLUID-BASED VISUAL PROGNOSTICATION IN TYPE 3 MACULAR NEOVASCULARIZATION-FLIP-3 STUDY. <i>Retina</i> , 2022, 42, 107-113.	1.0	16
6	Semaglutide and the risk of diabetic retinopathyâ€”current perspective. <i>Eye</i> , 2022, 36, 10-11.	1.1	12
7	Brolicizumabâ€™ early experience with early extended interval regime in chronic centre involved diabetic macular oedema. <i>Eye</i> , 2022, 36, 358-360.	1.1	7
8	Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials. <i>Eye</i> , 2022, 36, 679-680.	1.1	5
9	Brolicizumab â€™ termination of 4 weekly trials â€™ rebalancing the immunogenicity risk. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 441-443.	1.4	10
10	On label bevacizumab for retina: where it stands. <i>Eye</i> , 2022, 36, 916-917.	1.1	5
11	Ranizurel safety evaluation in real-world -(RaSER) study. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 25, 101358.	0.4	4
12	Retina: a unique subspecialty in the biosimilar landscape. <i>Eye</i> , 2022, , .	1.1	2
13	The port delivery system with ranibizumab: understanding nuances for clinical use in the real world. <i>Expert Opinion on Biological Therapy</i> , 2022, , .	1.4	0
14	Brolicizumab in polypoidal choroidal vasculopathy. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 809-812.	1.4	0
15	Brolicizumabâ€™ early real-world experience: BREW study. <i>Eye</i> , 2021, 35, 1045-1047.	1.1	54
16	Brolicizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. <i>Eye</i> , 2021, 35, 1292-1294.	1.1	23
17	Biosimilars for Retinal Diseases: An Update. <i>American Journal of Ophthalmology</i> , 2021, 224, 36-42.	1.7	33
18	Notion of tolerating subretinal fluid in neovascular AMD: understanding the fine print before the injection pause. <i>British Journal of Ophthalmology</i> , 2021, 105, 149-150.	2.1	6

#	ARTICLE	IF	CITATIONS
19	Brolucizumabâ€™foreseeable workflow in the current scenario. Eye, 2021, 35, 1548-1550.	1.1	15
20	Understanding the Mechanisms of Fluid Development in Age-Related Macular Degeneration. Ophthalmology Retina, 2021, 5, 105-107.	1.2	9
21	Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1381-1383.	1.0	7
22	Re: Kunimoto etÂal.: Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study (Ophthalmology. 2020;127:1331â€“1334). Ophthalmology, 2021, 128, e30.	2.5	0
23	Vortex vein anastomosis and pachychoroidâ€™an evolving understanding. Eye, 2021, 35, 1545-1547.	1.1	5
24	The Port Delivery System with ranibizumabâ€™journey of mitigating vitreous hemorrhage. Eye, 2021, , .	1.1	9
25	Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation. British Journal of Ophthalmology, 2021, 105, 297-298.	2.1	6
26	Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression. Eye, 2020, 34, 422-423.	1.1	11
27	Brolucizumab: is extended VEGF suppression on the horizon?. Eye, 2020, 34, 424-426.	1.1	7
28	Brolucizimabâ€™leading an era of structural revolution for long-term VEGF suppression. Eye, 2020, 34, 611-613.	1.1	16
29	Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populationsâ€™GEODEX-IOP study. Eye, 2020, 34, 1063-1068.	1.1	14
30	Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye, 2020, 34, 797-801.	1.1	15
31	Ophthalmic biosimilars and biologicsâ€™role of endotoxins. Eye, 2020, 34, 614-615.	1.1	11
32	Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. British Journal of Ophthalmology, 2020, 104, 2-7.	2.1	29
33	Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CIDME): a randomized study. International Ophthalmology, 2020, 40, 67-72.	0.6	10
34	MIIRetCam (Make In India Retina Camera) assisted retinal imaging in paediatric patients: Useful, artefacts, learning curve. Journal Francais D'Ophthalmologie, 2020, 43, e35-e38.	0.2	3
35	Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye, 2020, 34, 1008-1009.	1.1	16
36	Faricimab: expanding horizon beyond VEGF. Eye, 2020, 34, 802-804.	1.1	54

#	ARTICLE	IF	CITATIONS
37	Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. <i>Eye</i> , 2020, 34, 1006-1007.	1.1	13
38	Brolucizumab: the road ahead. <i>British Journal of Ophthalmology</i> , 2020, 104, 1631-1632.	2.1	5
39	Brolucizumab-key learnings from HAWK and HARRIER. <i>Eye</i> , 2020, 34, 1318-1320.	1.1	3
40	Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study. <i>International Ophthalmology</i> , 2020, 40, 3067-3075.	0.6	5
41	MII RetCam assisted smartphone-based fundus imaging (MSFI)â€”A boon for paediatric retinal imaging. <i>Eye</i> , 2020, 34, 1307-1309.	1.1	9
42	Smartphone based ROP (S-ROP) screeningâ€”opportunities and challenges. <i>Eye</i> , 2020, 34, 1512-1514.	1.1	7
43	Brolucizumab and immunogenicity. <i>Eye</i> , 2020, 34, 1726-1728.	1.1	34
44	Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum. <i>Eye</i> , 2020, 34, 1501-1503.	1.1	7
45	Brolucizumabâ€”another anti-VEGF or beyond. <i>Eye</i> , 2020, 34, 1499-1500.	1.1	7
46	Role of retinal image-based counseling in the treatment of peripheral retinal lesions. <i>Eye</i> , 2019, 33, 161-163.	1.1	2
47	Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management. <i>Ophthalmology Retina</i> , 2019, 3, 1009-1011.	1.2	1
48	Comparison of a Smartphone-Based Photography Method with Indirect Ophthalmoscopic Assessment in Referable Retinopathy of Prematurity. <i>Ophthalmology Retina</i> , 2019, 3, 911-912.	1.2	17
49	Re: Campochiaro etÂal.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (<i>Ophthalmology</i>). <i>Tj ETQq1 1 0.784314 rgBT. #Overlock 10 Tf 5</i>		
50	Biologics, biosilimars, and biobetters: different terms or different drugs?. <i>Eye</i> , 2019, 33, 1032-1034.	1.1	10
51	Biotherapeutics and immunogenicity: ophthalmic perspective. <i>Eye</i> , 2019, 33, 1359-1361.	1.1	19
52	Re: Dugel etÂal: HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration (<i>Ophthalmology</i> . 2019 Apr 12 [Epub] <i>Tj ETQq0 0 0rgBT /Overlock 10 Tf</i>		
53	Understanding Intravitreal Silicone Oil Droplets Due to Intravitreal Injections. <i>Retina</i> , 2019, Publish Ahead of Print, 1233-1235.	1.0	4
54	Biosimilars in ophthalmology: “Is there a big change on the horizon?”. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 2137-2143.	0.9	66

#	ARTICLE	IF	CITATIONS
55	Effects of light on retinal pigment epithelial cells, neurosensory retinal cells and Müller cells treated with Brilliant Blue G. Clinical and Experimental Ophthalmology, 2015, 43, 820-829.	1.3	12
56	Effects of dexamethasone on human trabecular meshwork cells in vitro. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1741-1746.	1.0	5
57	Fear of safety compromise with biosimilar anti-VEGF "perception or truth. Eye, , .	1.1	2